09000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In se Application of:

Bernd Riedl et al.

TRAD Serial No.: 10/086,417

Group Art Unit: UNASSIGNED

Filed: March 4, 2002

Examiner: UNASSIGNED

For: ω -CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Assistant Commissioner for Patents Washington, D. C. 20231

Sir:

CITED MATERIALS

Applie	cant(s) I	hereby disclose the information listed in the attached form PTO-	1449.			
	Copies of materials listed but not attached were cited in parent application Serial No; see 37 C.F.R. § 1.98(d).					
	Copies of materials listed but not attached were cited in an International Search Report dated; receipt of the International Search Report and copies of references was confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed					
<u>ADDI</u>	TIONA	L INFORMATION				
[NON]	E?]					
LANC	GUAGE		,			
	All lis	ted materials are in the English language; see 37 C.F.R. § 1.98.				
	Non-E	English language references:				
	comm	The reference(s): in the English-language is (are) indicercial data bases to correspond to the reference(s): , respec	•			
	□ provid	(An) English-language translation(s) of the references: led.	is (are)			
	□ provid	A commercial English-language abstract of reference(s) led.	is (are)			

An English-language search report or an equivalent paper from a foreign patent office translated into English in pertinent part in connection with a counterpart foreign application, is provided indicating the relevance of the cited reference(s). **FEES** \boxtimes No fee is required for this Information Disclosure Statement because: This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application; This Information Disclosure Statement is being filed before the mailing of a first action on the merits; This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below. This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(i). A fee is required for this Information Disclosure Statement: This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in §1.17(p). This Information Disclosure Statement is being filed after the mailing date of a final rejection or a notice of allowance under § 1.311 or an action that closes prosecution, but before the payment of the issue fee, and is accompanied by the fee set forth in § 1.17(p) and a certification below. **CERTIFICATION** Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, no such item was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

If a fee is due, attached is a check in the amount of \$____. However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Richard J. Traverso, Reg. No. 30,595 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza l
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333

Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Attorney Docket No.: BAYER 16 P2

Date: April 2, 2002

RJT:lvb

K:\Bayer\16p2\IDS 3-29-02.doc

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of Section persons are about ed to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known				
Application Number	10/086,417			
Filing Date	March 4, 2002			
First Named Inventor	Bernd Riedl et al.			
Group Art Unit	TO BE ASSIGNED			
Examiner Name	TO BE ASSIGNED			
Attorney Docket Number	BAYER 16 P2			

	Cite No.1	U.S. Patent Docu Number Kind C	 Name of Patentee or Applicant	D (D.)	
CM		I (II KIIO	of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Rele Passages or Relevant Figures Appear
OW		5,965,573	 Petrie er al.	10-12-99	
	·	6,093,742	Salituro et al.	7-25-00	
1		6,218,539 B1	Widdowson	4-17-01	
		6,242,601 B1	Breu et al.	6-5-01	
		6,004,965	Breu et al.	12-21-99	
		5,891,895	Shiraishi et al.	4-6-99	
		6,174,901 B	Mantlo et al.	1-16-01	
		6,339,045 B1	 Kanno et al.	1-15-02	
		6,005,008	 Widdowson et al.	12-21-99	
		5,908,865	 Doi et al.	6-1-99	
		6,180,675 B1	Widdowson et al.	1-30-01	
		6,211,373 B1	Widdowson et al.	4-3-01	
		5,780,483	Widdowson et al.	7-14-98	
		6,133,319	Widdowson	10-17-00	
		5,886,044	Widdowson et al.	3-23-99	
		6,020,345	Vacher et al.	2-1-00	-
		6,262,113 B1	Widdowson et al.	7-17-01	
		6,333,341 B1	Mantlo et al.	12-25-01	
		6,271,261 B1	 Widdowson	8-7-01	
		5,773,459	Tang et al.	6-30-98	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document			Name of Patentee	Date of Publication of	Pages, Columns, Lines, Where Relevant	
		Office ³		d Code ⁵ <i>known</i>)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	vvnere Helevant Passages or Relevant Figures Appear	T ₆
		EP	116932A1			8-10-00		•
		wo	97/30992			8-28-97	· -	
		EP	0860433A1			8-26-98		
		wo	98/17267			4-30-98		
		wo	99/32487			7-1-99		
		wo	97/17329			5-15-97		

<i>-</i>	M 10 - 1 - 10 - 10 - 10 - 10 - 10 - 10 -		
Examiner Signature		Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.